Loading…

Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial

Ivermectin is being considered for mass drug administration for malaria due to its ability to kill mosquitoes feeding on recently treated individuals. However, standard, single doses of 150–200 μg/kg used for onchocerciasis and lymphatic filariasis have a short-lived mosquitocidal effect (

Saved in:
Bibliographic Details
Published in:The Lancet infectious diseases 2018-06, Vol.18 (6), p.615-626
Main Authors: Smit, Menno R, Ochomo, Eric O, Aljayyoussi, Ghaith, Kwambai, Titus K, Abong'o, Bernard O, Chen, Tao, Bousema, Teun, Slater, Hannah C, Waterhouse, David, Bayoh, Nabie M, Gimnig, John E, Samuels, Aaron M, Desai, Meghna R, Phillips-Howard, Penelope A, Kariuki, Simon K, Wang, Duolao, Ward, Steve A, ter Kuile, Feiko O
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ivermectin is being considered for mass drug administration for malaria due to its ability to kill mosquitoes feeding on recently treated individuals. However, standard, single doses of 150–200 μg/kg used for onchocerciasis and lymphatic filariasis have a short-lived mosquitocidal effect (
ISSN:1473-3099
1474-4457
DOI:10.1016/S1473-3099(18)30163-4